LARSEN-&-TOUBRO
19.5.2020 19:31:14 CEST | Business Wire | Press release
Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q4 FY20 and full year FY20 results today.
Q4 FY20
In US Dollars:
- Revenue at USD 409.9 million ; growth of 3.9% QoQ and 15.9% YoY
- Constant Currency Revenue growth of 4.7% QoQ and 17.4% YoY
In Indian Rupees:
- Revenue at Rs 30,119 million ; growth at 7.1% QoQ and 21.2% YoY
- Net Income at Rs 4,275 million ; Net Income growth at 13.5% QoQ and 12.9% YoY
Full year FY20
In US Dollars:
- Revenue at USD 1,524.7 million ; growth of 13.0% YoY
- Constant Currency Revenue growth of 14.2% YoY
In Indian Rupees:
- Revenue at Rs 108,786 million ; growth at 15.2% YoY
- Net Income at Rs 15,205 million ; Net Income growth at 0.3% YoY
Capital Return
- Final Dividend of Rs 15.5 per share ; Dividend pay-out ratio of 35.0% for the year
- ROE of 29.5% for the year
“We are extremely proud of the strong work ethic of LTItes who rose to the challenge of an unparalleled global pandemic, exceeding client expectations and earning their trust.
Our resilient business model, comprehensive digital transformation capabilities and flawless execution helped us to deliver fourth consecutive year of industry leading double-digit revenue growth in FY20. We are also pleased to announce two large deals in Q4 with net-new TCV in excess of US$100 million, culminating in a record 8 large deal wins for us in FY20.
With strong order wins, healthy revenue momentum and client centric growth strategy, we shall confront near term demand challenges and emerge stronger.”
- Sanjay Jalona, Chief Executive Officer & Managing Director
Recent Deal Wins
- Multi-year multi-million large deal for complete digital transformation, enhancing productivity and quality of service of a key government ministry by implementing new microservices based applications and building a data and analytics platform
- A large energy retail company selected LTI for an end to end managed services deal for its IT applications and infrastructure operations
- Standard Chartered Bank chose LTI as its partner for a strategic Temenos T24 Transact engagement
- Leading North American bank selected LTI to transition its applications to cloud
- Global semiconductor major partnered with LTI to digitize its core by re-designing and implementing its critical processes on SAP S/4 HANA
- A leading property and casualty insurance company chose LTI as its business transformation partner to implement Duck Creek OnDemand Cloud Platform
- Global media broadcasting giant selected LTI to redesign and modernize its programming and scheduling applications to meet evolving business requirements
- A leading financial services group chose LTI for AMS engagement
Awards and Recognitions
- Recognized by the 1Q20 Global ISG Index™ as one of The Breakthrough 15 in Global, Americas, EMEA Sourcing Standouts
- LTI recognized as a Leader in ISG Provider Lens™: SIAM/ITSM 2020 Study for US Market
- LTI featured in Constellation ShortList: Innovation Services and Engineering for Q1 2020
- LTI recognized in Forrester's Now Tech: IoT Consultancies In Asia Pacific, Q1 2020
- LTI named in Honorable Mentions in the 2020 Gartner Magic Quadrant for Data and Analytics Service Providers
* Magic Quadrant for Data and Analytics Service, Worldwide, Jorgen Heizenberg et al., 10 February 2020. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose
Other Business Highlights
- The Board of Directors at its meeting held on May 19th , 2020 have declared a final dividend of Rs. 15.5 per equity share (Face value of Re. 1) for the financial year 2019-20. Total dividend for FY20 is Rs. 28 per equity share, including the interim dividend of Rs. 12.5 per equity share declared in October 2019.
- Won the SAP Pinnacle Award for Industry Innovation Partner of the Year 2020
- LTI has been elevated to a ‘GOLD’ partner status with Pega
- LTI is now a 'Premier' System Integration Partner with MuleSoft
- LTI has been featured among top 10 companies investing in EdTech CSR projects by CSRBOX
- The company’s long-term rating has been upgraded by CRISIL to AAA/Stable from AA+/Positive during the year
- National Stock Exchange of India Ltd. (NSE) has included LTI in its Nifty Next 50 Index
About LTI
LTI (NSE: LTI) is a global technology consulting and digital solutions Company helping more than 420 clients succeed in a converging world. With operations in 32 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI’s Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivaled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 30,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees and shareholders. Find more at http://www.Lntinfotech.com or follow us at @LTI_Global
Connect with LTI:
- Read our News and Blogs
- Follow us on Twitter and LinkedIn
- Like us on Facebook
- Watch our videos on YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005841/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom